Integrating Insilico Discovery software and Genedata Selector provides an organism-agnostic and comprehensive software platform that handles everything from strain genome information management to bioprocess modeling.
Munich, Germany (PRWEB) September 19, 2012
Genedata, a leading provider of advanced software solutions for industrial biotechnology, drug discovery and life science research, and Insilico Biotechnology, a premier provider of advanced solutions for genome-scale simulations, today announced the integration of their technologies, which creates an end-to-end platform for industrial biotechnology research. The platform integrates Genedata Selector™ for comprehensive genome management and data analysis with Insilico Discovery™ simulation software. SysEnCor, a German research consortium, will use the integrated platform to analyze the energy metabolism of Corynebacterium glutamicum, a key organism for bioprocessed amino acids used in food and feed production.
“By integrating our respective platforms, Genedata and Insilico Biotechnology offer a solution that empowers companies to combine quantitative biotechnology with hypothesis generation with experimental validation,” said Klaus Mauch, CEO of Insilico Biotechnology. “The integration of Insilico Biotechnology and Genedata Selector software paves the way for innovative strain optimization and fermentation processes in areas such as feed and food additives, care specialties, and therapeutic precursors,” noted Dr. Othmar Pfannes, CEO of Genedata.
SysEnCor Innovates Strain Development
Cost factors in large-scale biotechnological production processes include feedstock, the efficiency of microorganism conversion to product, and the ability to quickly obtain high yields. C. glutamicum optimization requires a comprehensive understanding of genetic make-up, functional characterization of macromolecules and their interactions, and identification of underlying metabolic and regulatory networks controlling strain growth and productivity. SysEnCor applies advanced systems biotechnology to quantify, understand and design energy metabolism in developing novel production strains.
Co-funded by the German Federal Ministry of Education and Research, SysEnCor is comprised of Evonik Degussa, Genedata, Insilico Biotechnology and seven academic institutions. Using mathematical modeling and simulation, high-throughput molecular profiling, and innovative data analysis for next-generation sequencing data, SysEnCor is pioneering stress-tolerant and efficient microbial strains for the synthesis of amino acids such as arginine and histidine. Collaborating with SysEnCor and its industrial partners, Genedata is integrating Genedata Selector − the only system for complete mapping of all omics and pathway data − with Insilico Discovery, the only system for obtaining fluxome data and dynamic network simulations. The resulting platform will significantly enhance genome-wide dynamic models of C. glutamicum while streamlining and accelerating strain development cycles.
“Integrating Insilico Discovery software and Genedata Selector provides an organism-agnostic and comprehensive software platform that handles everything from strain genome information management to bioprocess modeling,” continued Dr. Pfannes. “Our collaboration with Insilico Biotechnology and involvement with SysEnCor reflects our long-standing and continuously expanding presence in the industrial biotech sector, and underscores the companies’ commitment to innovative industrial biotech solutions.”
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US. http://www.genedata.com.
About Insilico Biotechnology
Insilico Biotechnology is a market-leading company providing solutions and software for the simulation of living cells. An interdisciplinary team of experts offers customized solutions for the efficient manufacturing of biotechnological products and for the development of drug test systems by using high-performance computing and Insilico's proprietary software. For world-leading companies from the chemical and pharmaceutical industries, Insilico's technology lowers time, risk and costs of development processes. Founded in 2001, Insilico is a privately held company based in Stuttgart, Germany. For further information, please visit http://www.insilico-biotechnology.com.
Marketing & Communications Genedata
Phone: +41 61 511 8459
Dr. Heike Lehmann
Insilico Biotechnology AG
Phone: +49 711 460 594-18
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.